BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed C ...
Cancer doctor shares which five types of the disease are most 'lethal'
A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with them usually have less than a year to live ...
American Association of Individual Investors39m
Which Is a Better Investment, Amicus Therapeutics, Inc. or Merus N.V. Stock?
Learn more about whether Amicus Therapeutics, Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...
Le Lézard28m
RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center
RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center ...